124 related articles for article (PubMed ID: 6165370)
21. Lymphocyte-mediated cytotoxicity against gliomas.
Rainbird S; Allwood G; Ridley A
Brain; 1981 Sep; 104(3):451-64. PubMed ID: 7272710
[TBL] [Abstract][Full Text] [Related]
22. Failure to induce transplantation immunity to an SV40-induced tumour in hamsters immunized with basic proteins of myelin or malignant tissues.
Flavell DJ; Potter CW
Br J Cancer; 1978 Jul; 38(1):151-3. PubMed ID: 80222
[No Abstract] [Full Text] [Related]
23. [Immunologic sensitization to tumor-associated antigens during the growth of gliomas of the brain (experimental study)].
Novichenko NL; Romodanov AP; Zhmareva EN; Gorovoĭ AI
Zh Vopr Neirokhir Im N N Burdenko; 1984; (2):9-13. PubMed ID: 6741378
[TBL] [Abstract][Full Text] [Related]
24. Pre- and postoperative changes in serum myelin basic protein immunoreactivity in neurosurgical patients.
Hoyle NR; Seeldrayers PA; Moussa AH; Paul EA; Thomas DG
J Neurosurg; 1984 Jul; 61(1):49-52. PubMed ID: 6202857
[TBL] [Abstract][Full Text] [Related]
25. Lymphocyte sensitization to basic protein of brain in malignant neoplasia: experiments with serotonin and related compounds.
Field EJ; Caspary EA; Carnegie PR
Nature; 1971 Sep; 233(5317):284-6. PubMed ID: 4106472
[No Abstract] [Full Text] [Related]
26. [Effects of dexamethasone on the depression of lymphocyte immune response in the experimental rats with transplanted glioma].
Huang Q
Zhonghua Zhong Liu Za Zhi; 1984 Jul; 6(4):244-6. PubMed ID: 6525938
[No Abstract] [Full Text] [Related]
27. Evaluation of macrophage electrophoretic mobility (MEM) test as an indicator of cellular immunity in ocular tumours.
Rahi AH; Otiko G; Winder AF
Br J Ophthalmol; 1976 Aug; 60(8):589-93. PubMed ID: 61762
[TBL] [Abstract][Full Text] [Related]
28. Reactivity of tumor-infiltrating, blood, spleen and lymph node lymphocytes against syngeneic glioma target cells.
Stavrou D; Bilzer T; Anzil AP; Hultén M; Kaldrymidou E
Anticancer Res; 1981; 1(3):125-34. PubMed ID: 7342850
[TBL] [Abstract][Full Text] [Related]
29. Immunoreactive myelin basic protein in tumor cells associated with carcinomatous neuropathy.
Kudo M; Noguchi T
Am J Clin Pathol; 1985 Dec; 84(6):741-3. PubMed ID: 2416217
[TBL] [Abstract][Full Text] [Related]
30. The macrophage electrophoretic mobility (MEM) test for malignant disease. Further clinical investigations and studies on macrophage slowing factors.
Preece AW; Light PA
Clin Exp Immunol; 1974 Dec; 18(4):543-52. PubMed ID: 4143199
[TBL] [Abstract][Full Text] [Related]
31. [Cellular immunity of the patients with malignant glioma -- with special reference to the depressed cell-mediated immunity of the cerebrospinal (author's transl)].
Uemura S; Wada S; Kodama T; Matsukado Y
No Shinkei Geka; 1977 Aug; 5(9):931-9. PubMed ID: 303336
[No Abstract] [Full Text] [Related]
32. Technical aspects of the macrophage electrophoretic mobility (MEM) test for malignant disease.
Pritchard JA; Moore JL; Sutherland WH; Joslin CA
Br J Cancer Suppl; 1973 Aug; 1():229-36. PubMed ID: 4804283
[TBL] [Abstract][Full Text] [Related]
33. Studies with the macrophage migration inhibition (MMI) test in patients with malignant disease.
Light PA; Preece AW; Waldron HA
Clin Exp Immunol; 1975 Nov; 22(2):279-84. PubMed ID: 55328
[TBL] [Abstract][Full Text] [Related]
34. [Sensitization of lymphocytes of the cerebrospinal fluid and blood to myelin basic proteins and glycolipids in subacute sclerosing panencephalitis].
Członkowska A; Vainiene M; Rzepecki Z; Półtorak M; Korlak J
Neurol Neurochir Pol; 1986; 20(1):6-11. PubMed ID: 2423909
[TBL] [Abstract][Full Text] [Related]
35. Spinal fluid basic protein immunoreactive material and spinal fluid lymphocyte reactivity to basic protein.
Lisak RP; Zweiman B; Whitaker JN
Neurology; 1981 Feb; 31(2):180-2. PubMed ID: 6162132
[TBL] [Abstract][Full Text] [Related]
36. Comparison between the macrophage electrophoretic mobility (MEM) and the fixed tanned erythrocyte electrophoretic mobility (FTEEM) tests in the detection of cancer.
Harlos JP; Weiss L
Int J Cancer; 1978 Apr; 21(4):413-7. PubMed ID: 78907
[TBL] [Abstract][Full Text] [Related]
37. Reactivity in the MEM-test of cancer patients' lymphocytes incubated with brain-derived preparations and extracts from malignant teratomas.
Müller M; Irmscher J; Grossmann H; Kotzsch M; Wagner H; Kemmer C
Arch Geschwulstforsch; 1981; 51(4):354-63. PubMed ID: 6172087
[TBL] [Abstract][Full Text] [Related]
38. [Immunology of brain tumors: immunological situation of the brain].
Tanaka R; Sobue H
No To Shinkei; 1983 May; 35(5):451-9. PubMed ID: 6354218
[No Abstract] [Full Text] [Related]
39. Tumor markers: malignin and related recognins associated with malignancy rather than with cell type.
Bogoch S; Bogoch ES
Prog Clin Biol Res; 1980; 39():407-24. PubMed ID: 7403189
[No Abstract] [Full Text] [Related]
40. [The electrophoretic-mobility-(EM) test: a method for discrimination of malignant and non-malignant tumors (author's transl)].
Tautz C; Schneider W; Laier E; Brügmann G
Klin Wochenschr; 1978 Feb; 56(4):175-85. PubMed ID: 75286
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
